Cytek Biosciences Analyst Ratings
Cytek Biosciences Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 10/24/2023 | 73.16% | Morgan Stanley | $13 → $8 | Maintains | Equal-Weight |
| 10/16/2023 | 116.45% | Piper Sandler | $15 → $10 | Maintains | Overweight |
| 07/19/2023 | — | Raymond James | Initiates Coverage On | → Market Perform | |
| 05/11/2023 | 181.39% | Morgan Stanley | $14 → $13 | Maintains | Equal-Weight |
| 05/10/2023 | 159.74% | Goldman Sachs | $14 → $12 | Maintains | Buy |
| 03/07/2023 | 224.68% | Piper Sandler | $18 → $15 | Maintains | Overweight |
| 03/02/2023 | 203.03% | Morgan Stanley | $15 → $14 | Maintains | Equal-Weight |
| 03/02/2023 | 203.03% | Goldman Sachs | $16 → $14 | Maintains | Buy |
| 08/18/2022 | 246.32% | Piper Sandler | $12 → $16 | Maintains | Overweight |
| 08/12/2022 | 224.68% | Morgan Stanley | $11 → $15 | Maintains | Equal-Weight |
| 08/11/2022 | 267.97% | Goldman Sachs | $15 → $17 | Maintains | Buy |
| 07/14/2022 | 224.68% | Goldman Sachs | $12 → $15 | Maintains | Buy |
| 05/16/2022 | 159.74% | Piper Sandler | $17 → $12 | Maintains | Overweight |
| 05/13/2022 | 138.1% | Morgan Stanley | $18 → $11 | Maintains | Equal-Weight |
| 05/12/2022 | 159.74% | Goldman Sachs | $14 → $12 | Maintains | Buy |
| 04/13/2022 | 203.03% | Goldman Sachs | $28 → $14 | Maintains | Buy |
| 02/15/2022 | 289.61% | Morgan Stanley | $27 → $18 | Maintains | Equal-Weight |
| 08/17/2021 | — | Cowen & Co. | Initiates Coverage On | → Outperform | |
| 08/17/2021 | 462.77% | Morgan Stanley | → $26 | Initiates Coverage On | → Equal-Weight |
| 08/17/2021 | 506.06% | Goldman Sachs | → $28 | Initiates Coverage On | → Buy |
| 08/17/2021 | 506.06% | Piper Sandler | → $28 | Initiates Coverage On | → Overweight |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 2023年10月24日 | 73.16% | 摩根士丹利 | $13→$8 | 維護 | 等重 |
| 10/16/2023 | 116.45% | 派珀·桑德勒 | $15→$10 | 維護 | 超重 |
| 07/19/2023 | - | 雷蒙德·詹姆斯 | 開始承保 | →市場表現 | |
| 2023年05月11日 | 181.39% | 摩根士丹利 | $14→$13 | 維護 | 等重 |
| 2023年05月10日 | 159.74% | 高盛 | $14→$12 | 維護 | 買 |
| 03/07/2023 | 224.68% | 派珀·桑德勒 | $18→$15 | 維護 | 超重 |
| 03/02/2023 | 203.03% | 摩根士丹利 | $15→$14 | 維護 | 等重 |
| 03/02/2023 | 203.03% | 高盛 | $16→$14 | 維護 | 買 |
| 2022/08/18 | 246.32% | 派珀·桑德勒 | $12→$16 | 維護 | 超重 |
| 2022年08月12日 | 224.68% | 摩根士丹利 | $11→$15 | 維護 | 等重 |
| 2022年08月11日 | 267.97% | 高盛 | $15→$17 | 維護 | 買 |
| 07/14/2022 | 224.68% | 高盛 | $12→$15 | 維護 | 買 |
| 05/16/2022 | 159.74% | 派珀·桑德勒 | $17→$12 | 維護 | 超重 |
| 2022年05月13日 | 138.1% | 摩根士丹利 | $18→$11 | 維護 | 等重 |
| 2022年05月12日 | 159.74% | 高盛 | $14→$12 | 維護 | 買 |
| 04/13/2022 | 203.03% | 高盛 | $28→$14 | 維護 | 買 |
| 02/15/2022 | 289.61% | 摩根士丹利 | $27→$18 | 維護 | 等重 |
| 2021/08/17 | - | 考恩公司 | 開始承保 | →跑贏大盤 | |
| 2021/08/17 | 462.77% | 摩根士丹利 | →$26 | 開始承保 | →等重 |
| 2021/08/17 | 506.06% | 高盛 | →$28 | 開始承保 | →購買 |
| 2021/08/17 | 506.06% | 派珀·桑德勒 | →$28 | 開始承保 | →超重 |
What is the target price for Cytek Biosciences (CTKB)?
賽特克生物科學公司(CTKB)的目標價格是多少？
The latest price target for Cytek Biosciences (NASDAQ: CTKB) was reported by Morgan Stanley on October 24, 2023. The analyst firm set a price target for $8.00 expecting CTKB to rise to within 12 months (a possible 73.16% upside). 8 analyst firms have reported ratings in the last year.
賽特克生物科學(納斯達克：CTKB)的最新目標價是由摩根士丹利於2023年10月24日報道的。這家分析公司將目標價定為8.00美元，預計CTKB將在12個月內上漲至73.16%(可能上漲73.16%)。去年有8家分析公司公佈了評級。
What is the most recent analyst rating for Cytek Biosciences (CTKB)?
Cytek Biosciences(CTKB)的最新分析師評級是什麼？
The latest analyst rating for Cytek Biosciences (NASDAQ: CTKB) was provided by Morgan Stanley, and Cytek Biosciences maintained their equal-weight rating.
賽特克生物科技(納斯達克：CTKB)的最新分析師評級由摩根士丹利提供，賽特克生物科技維持同等權重評級。
When is the next analyst rating going to be posted or updated for Cytek Biosciences (CTKB)?
Cytek Biosciences(CTKB)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Cytek Biosciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Cytek Biosciences was filed on October 24, 2023 so you should expect the next rating to be made available sometime around October 24, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括查閱公共財務報表，與Cytek Biosciences的高管和客戶交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。Cytek Biosciences的上一次評級是在2023年10月24日提交的，所以你應該預計下一次評級將在2024年10月24日左右的某個時候提供。
Is the Analyst Rating Cytek Biosciences (CTKB) correct?
分析師對Cytek Biosciences(CTKB)的評級正確嗎？
While ratings are subjective and will change, the latest Cytek Biosciences (CTKB) rating was a maintained with a price target of $13.00 to $8.00. The current price Cytek Biosciences (CTKB) is trading at is $4.62, which is out of the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但Cytek Biosciences(CTKB)的最新評級保持不變，目標價在13.00美元至8.00美元之間。Cytek Biosciences(CTKB)目前的交易價格為4.62美元，超出了分析師的預測區間。